Search

Displaying results 2321 - 2330 of 8696 in total
  1. Drug

    Valdecoxib

    go.drugbank.com/drugs/DB00580
    ApprovedWithdrawn

    Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Cenegermin

    go.drugbank.com/drugs/DB13926
    ApprovedInvestigational

    The approval of cenegermin consequently provides a novel topical treatment that has the potential capacity to offer total corneal healing for many patients who may use the agent. … Many currently available therapeutic options for treating the condition involve surgical interventions - surgeries that are typically only palliative [L4563].

  3. Drug

    Manidipine

    go.drugbank.com/drugs/DB09238
    ApprovedInvestigationalWithdrawn

    It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages. … Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 Inhibitors
  4. Drug

    Sulfoxone

    go.drugbank.com/drugs/DB01145
    Approved

    Sulfoxone is a water-soluble sulfone used as an antileprosy drug. It has been used with limited success in the treatment of dermatitis herpetiformis.

    Categories: Drugs for Treatment of Lepra, Antiinfectives for Systemic Use
  5. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    (rhCNTF) (NTC-201-6A cell line) for surgical intravitreal placement. … [A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2.

    Synonyms: An allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmid
  6. Drug

    Menadione

    go.drugbank.com/drugs/DB00170
    ApprovedNutraceutical

    A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 Inhibitors
  7. Drug

    Gavorestat

    go.drugbank.com/drugs/DB16707
    Investigational

    Gavorestat is under investigation in clinical trial NCT04902781 (Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia).

  8. Drug

    Relacorilant

    go.drugbank.com/drugs/DB14976
    ApprovedInvestigational

    [L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist.

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2C8 Inducers
  9. Drug

    Tranylcypromine

    go.drugbank.com/drugs/DB00752
    ApprovedInvestigational

    An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).

    Categories: Antidepressive Agents Indicated for Depression, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  10. Drug

    Olutasidenib

    go.drugbank.com/drugs/DB16267
    ApprovedInvestigational

    [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. … [A254726,L44256] Other IDH1 inhibitors, such as [ivosidenib], have also been approved for the treatment of relapsed or refractory AML.

    Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitors